Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study
Key facts
- Who runs it
- Kanglin Biotechnology (Hangzhou) Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 12 people, planned
- Starts
- Jan 2027
- Expected to end
- Oct 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Injecting KL002 into the bilateral putamen
- Record updated
- 16 November 2026
Who can take part
- Age
- 40 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Clinically diagnosed primary PD
- Males or females ≥ 40 and ≤ 75 years old
- History of Parkinson's disease diagnosis ≥ 5 years
- Regularly take stable equivalent doses of dopaminergic drugs (including levodopa) for at least 4 weeks before the screening period
- Good compliance and regular follow-up
Who cannot take part
- Have surgical contraindications or have undergone brain surgery in the past
- Prior severe allergic reactions or allergic to contrast agents or unable to accept surgical anesthesia
- Any type of prior gene or cell therapy
- Atypical or secondary Parkinson's syndrome
- Any indications of elevated intracranial pressure evaluated by investigator
- Abnormal liver and kidney function
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Parkinson's disease or advanced primary PD
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.
The 2 groups in the trial
- low dose groupTreatment being tested
Putamen stereotactic injection of low dose of KL002
Treatment: Injecting KL002 into the bilateral putamen
- high dose groupTreatment being tested
Putamen stereotactic injection of high dose of KL002
Treatment: Injecting KL002 into the bilateral putamen
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of KL002 Injection in the Striatal Putamen Region for Patients With Mid-to-Late Stage Primary Parkinson's Disease
- Criteria questions
- Built from NCT07939295, who can take part
- Record updated
- 16 November 2026